<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMBISOME- amphotericin b injection, powder, lyophilized, for solution </strong><br>Astellas Pharma US, Inc.<br></p></div>
<h1>AmBisome<span class="Sup">®</span>(amphotericin B) liposome for injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_adf1e82d-7a10-4111-b54f-123c5085e30a"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Am<span class="Bold">B</span>isome for Injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion. Each vial contains 50 mg of amphotericin B, USP, intercalated into a liposomal membrane consisting of approximately 213 mg hydrogenated soy phosphatidylcholine; 52 mg <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, NF; 84 mg distearoylphosphatidylglycerol; 0.64 mg alpha tocopherol, USP; together with 900 mg sucrose, NF; and 27 mg disodium succinate hexahydrate as buffer. Following reconstitution with Sterile Water for Injection, USP, the resulting pH of the suspension is between 5-6.</p>
<p>Am<span class="Bold">B</span>isome is a true single bilayer liposomal drug delivery system. Liposomes are closed, spherical <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> created by mixing specific proportions of amphophilic substances such as phospholipids and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> so that they arrange themselves into multiple concentric bilayer membranes when hydrated in aqueous solutions. Single bilayer liposomes are then formed by microemulsification of multilamellar <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> using a homogenizer. Am<span class="Bold">B</span>isome consists of these unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. Due to the nature and quantity of amphophilic substances used, and the lipophilic moiety in the amphotericin B molecule, the drug is an integral part of the overall structure of the Am<span class="Bold">B</span>isome liposomes. Am<span class="Bold">B</span>isome contains true liposomes that are less than 100 nm in diameter. A schematic depiction of the liposome is presented below.</p>
<p><img alt="description" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a&amp;name=3ab7fe3b-149e-4ff5-826a-1e23a6d39b55-01.jpg"></p>
<p>Note: Liposomal encapsulation or incorporation into a lipid complex can substantially affect a drug’s functional properties relative to those of the unencapsulated drug or non-lipid associated drug. In addition, different liposomal or lipid-complex products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component. Such differences may affect the functional properties of these drug products. </p>
<p>Amphotericin B is a macrocyclic, polyene, antifungal antibiotic produced from a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Streptomyces nodosus</span>. Amphotericin B is designated chemically as: </p>
<p>[1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*, 19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*)]-33-[(3-Amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid (CAS No. 1397-89-3).</p>
<p>Amphotericin B has a molecular formula of C<span class="Sub">47</span>H<span class="Sub">73</span>NO<span class="Sub">17</span> and a molecular weight of 924.09.</p>
<p>The structure of amphotericin B is shown below: </p>
<div class="Figure"><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a&amp;name=3ab7fe3b-149e-4ff5-826a-1e23a6d39b55-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e96e95a3-3016-4263-85a2-1ea488a21bd9"></a><a name="section-2"></a><p></p>
<h1>MICROBIOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_70e3d422-3103-45c4-8ef6-f79f29e47fbd"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Amphotericin B, the active ingredient of Am<span class="Bold">B</span>isome, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. It forms transmembrane channels leading to alterations in cell permeability through which monovalent ions (NA+, K+, H+, and Cl-) leak out of the cell resulting in <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>. While amphotericin B has a higher affinity for the ergosterol component of the fungal cell membrane, it can also bind to the <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> component of the mammalian cell leading to cytotoxicity. Am<span class="Bold">B</span>isome, the liposomal preparation of amphotericin B, has been shown to penetrate the cell wall of both extracellular and intracellular forms of susceptible fungi.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d673baf-210a-487d-adbb-a0c3d16ddb46"></a><a name="section-2.2"></a><p></p>
<h2>Activity In Vitro and In Vivo</h2>
<p class="First">Am<span class="Bold">B</span>isome has shown <span class="Italics">in vitro</span> activity comparable to amphotericin B against the following organisms: <span class="Italics">Aspergillus </span><span class="Italics"> fumigatus, Aspergillus flavus, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="Italics">albicans, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> lusitaniae, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis), <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">Cryptococcus neoformans</span>, </span>and<span class="Italics"> Blastomyces </span><span class="Italics">dermatitidis. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a702ade8-5044-438f-9cc8-ed26e2668af1"></a><a name="section-2.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First">Mutants with decreased susceptibility to amphotericin B have been isolated from several fungal species after serial passage in culture media containing the drug, and from some patients receiving prolonged therapy. Drug combination studies <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> suggest that imidazoles may induce resistance to amphotericin B. However, the clinical relevance of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_642f9ff6-59ec-4fa3-bd2a-c88d3b2c8fb6"></a><a name="section-2.4"></a><p></p>
<h2>Susceptibility Testing</h2>
<p class="First">Standardized methods of <span class="Italics">in vitro</span> antifungal susceptibility testing have been developed for testing yeasts (1, 2, 3) and filamentous fungi (4, 5). The clinical relevance of the test results is not always clear. </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_81f2f1a4-d864-4419-85c1-2f595311b2da"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e0b8aa80-cf3f-4ab7-8fcb-3a7b86208185"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics </h2>
<p class="First">The assay used to measure amphotericin B in the serum after administration of Am<span class="Bold">B</span>isome does not distinguish amphotericin B that is complexed with the phospholipids of Am<span class="Bold">B</span>isome from amphotericin B that is uncomplexed. The pharmacokinetic profile of amphotericin B after administration of Am<span class="Bold">B</span>isome is based upon total serum concentrations of amphotericin B. The pharmacokinetic profile of amphotericin B was determined in febrile neutropenic cancer and bone marrow transplant patients who received 1-2 hour infusions of 1 to 5 mg/kg/day Am<span class="Bold">B</span>isome for 3 to 20 days. </p>
<p>The pharmacokinetics of amphotericin B after administration of Am<span class="Bold">B</span>isome is nonlinear such that there is a greater than proportional increase in serum concentrations with an increase in dose from 1 to 5 mg/kg/day. The pharmacokinetic parameters of total amphotericin B (mean ± SD) after the first dose and at steady state are shown in the table below.</p>
<a name="id_6fcc5047-9035-4208-a0bc-ea86eb2c2060"></a><table border="single" width="592.000">
<caption><span>Pharmacokinetic Parameters of AmBisome</span></caption>
<col width="15.7%">
<col width="11.1%">
<col width="12.0%">
<col width="14.9%">
<col width="13.9%">
<col width="17.6%">
<col width="14.9%">
<thead>
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Dose<br>(mg/kg/day):</span></td>
<td class="Toprule" align="center" colspan="2" valign="top">
<span class="Bold">1</span> </td>
<td class="Toprule" align="center" colspan="2" valign="top"><span class="Bold">2.5</span></td>
<td align="center" colspan="2" valign="top">5</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><span class="Bold">Day</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1<br>n = 8</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Last<br>n = 7</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1<br>n = 7</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Last<br>n = 7</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">1<br>n = 12</span></td>
<td align="center" valign="top"><span class="Bold">Last<br>n = 9</span></td>
</tr>
</thead>
<tbody>
<tr class="First Toprule"><td align="left" colspan="7" valign="top"><span class="Bold">Parameters</span></td></tr>
<tr>
<td align="center" valign="top">C<span class="Sub">max</span> (mcg/mL)</td>
<td align="center" valign="top">7.3 ± 3.8</td>
<td align="center" valign="top">12.2 ± 4.9</td>
<td align="center" valign="top">17.2 ± 7.1</td>
<td align="center" valign="top">31.4 ± 17.8</td>
<td align="center" valign="top">57.6 ± 21</td>
<td align="center" valign="top">83 ± 35.2</td>
</tr>
<tr>
<td align="center" valign="top">AUC<span class="Sub">0-24 </span>(mcg•hr/mL)</td>
<td align="center" valign="top">27 ± 14</td>
<td align="center" valign="top">60 ± 20</td>
<td align="center" valign="top">65 ± 33</td>
<td align="center" valign="top">197 ± 183</td>
<td align="center" valign="top">269 ± 96</td>
<td align="center" valign="top">555 ± 311</td>
</tr>
<tr>
<td align="center" valign="top">t<span class="Sub">½</span>(hr)</td>
<td align="center" valign="top">10.7 ± 6.4</td>
<td align="center" valign="top">7 ± 2.1</td>
<td align="center" valign="top">8.1 ± 2.3</td>
<td align="center" valign="top">6.3 ± 2</td>
<td align="center" valign="top">6.4 ± 2.1</td>
<td align="center" valign="top">6.8 ± 2.1</td>
</tr>
<tr>
<td align="center" valign="top">V<span class="Sub">ss</span>(L/kg)</td>
<td align="center" valign="top">0.44 ± 0.27</td>
<td align="center" valign="top">0.14 ± 0.05</td>
<td align="center" valign="top">0.40 ± 0.37</td>
<td align="center" valign="top">0.16 ± 0.09</td>
<td align="center" valign="top">0.16 ± 0.10</td>
<td align="center" valign="top">0.10 ± 0.07</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top">Cl (mL/hr/kg)</td>
<td align="center" valign="top">39 ± 22</td>
<td align="center" valign="top">17 ± 6</td>
<td align="center" valign="top">51 ± 44</td>
<td align="center" valign="top">22 ± 15</td>
<td align="center" valign="top">21 ± 14</td>
<td align="center" valign="top">11 ± 6</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Based on total amphotericin B concentrations measured within a dosing interval (24 hours) after administration of Am<span class="Bold">B</span>isome, the mean half-life was 7-10 hours. However, based on total amphotericin B concentration measured up to 49 days after dosing of Am<span class="Bold">B</span>isome, the mean half-life was 100-153 hours. The long terminal elimination half-life is probably a slow redistribution from tissues. Steady state concentrations were generally achieved within 4 days of dosing.</p>
<p>Although variable, mean trough concentrations of amphotericin B remained relatively constant with repeated administration of the same dose over the range of 1 to 5 mg/kg/day, indicating no significant drug accumulation in the serum.</p>
<p><span class="Bold"> </span></p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>The metabolic pathways of amphotericin B after administration of Am<span class="Bold">B</span>isome are not known.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>The mean clearance at steady state was independent of dose. The excretion of amphotericin B after administration of Am<span class="Bold">B</span>isome has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8af596e3-a9ae-40c6-b785-7b6e5a9364d2"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics in Special Populations</h2>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the disposition of amphotericin B after administration of Am<span class="Bold">B</span>isome has not been studied. However, Am<span class="Bold">B</span>isome has been successfully administered to patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce">DESCRIPTION OF CLINICAL STUDIES</a>).</p>
<p><span class="Italics"> </span></p>
<p><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the disposition of amphotericin B after administration of Am<span class="Bold">B</span>isome is not known. </p>
<p><span class="Bold"> </span></p>
<p><span class="Bold"><span class="Italics">Pediatric and Elderly Patients</span></span></p>
<p>The pharmacokinetics of amphotericin B after administration of Am<span class="Bold">B</span>isome in pediatric and elderly patients has not been studied; however, Am<span class="Bold">B</span>isome has been used in pediatric and elderly patients (see <a href="#i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce">DESCRIPTION OF CLINICAL STUDIES</a>).</p>
<p><span class="Italics"><span class="Bold">Gender and Ethnicity</span></span></p>
<p>The effect of gender or ethnicity on the pharmacokinetics of amphotericin B after administration of Am<span class="Bold">B</span>isome is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_93825879-5c14-4023-ba37-b600b8cdc68b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Am<span class="Bold">B</span>isome is indicated for the following:</p>
<ul>
<li>Empirical therapy for presumed <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> in febrile, neutropenic patients.</li>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span> in HIV infected patients (see <a href="#i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce">DESCRIPTION OF CLINICAL STUDIES</a>).</li>
<li>Treatment of patients with <span class="Italics">Aspergillus </span>species, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species and/or <span class="Italics">Cryptococcus</span> species <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see above for the treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span>) refractory to amphotericin B deoxycholate, or in patients where <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or unacceptable toxicity precludes the use of amphotericin B deoxycholate. </li>
<li>Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with Am<span class="Bold">B</span>isome, relapse rates were high following initial clearance of parasites (see <a href="#i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce">DESCRIPTION OF CLINICAL STUDIES</a>).</li>
</ul>
<p>See <a href="#i4i_dosage_admin_id_dab5b8d8-3c39-4203-b40b-0c7f76d1adcd">DOSAGE AND ADMINISTRATION</a> for recommended doses by indication.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce"></a><a name="section-5"></a><p></p>
<h1>DESCRIPTION OF CLINICAL STUDIES</h1>
<p class="First">Eleven clinical studies supporting the efficacy and safety of Am<span class="Bold">B</span>isome were conducted. This clinical program included both controlled and uncontrolled studies<span class="Bold">. </span>These studies, which involved 2171 patients, included patients with confirmed systemic mycoses, empirical therapy, and visceral leishmaniasis. </p>
<p>Nineteen hundred and forty-six episodes were evaluable for efficacy, of which 1280 (302 pediatric and 978 adults) were treated with Am<span class="Bold">B</span>isome.</p>
<p>Three controlled empirical therapy trials compared the efficacy and safety of Am<span class="Bold">B</span>isome to amphotericin B. One of these studies was conducted in a pediatric population, one in adults, and a third in patients aged 2 years or more. In addition, a controlled empirical therapy trial comparing the safety of Am<span class="Bold">B</span>isome to Abelcet<span class="Sup">® </span>(amphotericin B lipid complex) was conducted in patients aged 2 years or more. </p>
<p>One controlled trial compared the efficacy and safety of Am<span class="Bold">B</span>isome to amphotericin B in HIV patients with <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>.</p>
<p>One compassionate use study enrolled patients who had failed amphotericin B deoxycholate therapy or who were unable to receive amphotericin B deoxycholate because of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_08b81a5f-ad43-4ad8-8743-f106075de143"></a><a name="section-5.1"></a><p></p>
<h2>Empirical Therapy in Febrile Neutropenic Patients</h2>
<p class="First">Study 94-0-002, a randomized, double-blind, comparative multi-center trial, evaluated the efficacy of Am<span class="Bold">B</span>isome (1.5-6 mg/kg/day) compared with amphotericin B deoxycholate (0.3-1.2 mg/kg/day) in the empirical treatment of 687 adult and pediatric neutropenic patients who were febrile despite having received at least 96 hours of broad spectrum antibacterial therapy. Therapeutic success required (a) resolution of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> during the neutropenic period, (b) absence of an emergent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, (c) patient survival for at least 7 days post therapy, (d) no discontinuation of therapy due to toxicity or lack of efficacy, and (e) resolution of any study-entry <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>. </p>
<p>The overall therapeutic success rates for Am<span class="Bold">B</span>isome and the amphotericin B deoxycholate were equivalent. Results are summarized in the following table. Note: The categories presented below are not mutually exclusive.</p>
<a name="id_b62f051d-e4b1-4603-be44-862caebcc258"></a><table border="single" width="511.000">
<caption><span>Empirical Therapy in Febrile Neutropenic Patients: Randomized, Double-Blind Study in 687 Patients</span></caption>
<col width="40.7%">
<col width="27.0%">
<col width="32.3%">
<thead><tr class="Botrule First Last">
<td align="center" valign="top"><p class="First"> </p></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">AmBisome</span></td>
<td align="center" valign="top"><span class="Bold">Amphotericin B</span></td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd> 8 and 10 patients, respectively, were treated as failures due to premature discontinuation alone.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Number of patients receiving at least one dose of study drug</td>
<td class="Toprule" align="center" valign="top">343</td>
<td align="center" valign="top">344</td>
</tr>
<tr>
<td align="left" valign="top">Overall Success</td>
<td align="center" valign="top">171 (49.9%)</td>
<td align="center" valign="top">169 (49.1%)</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> resolution during </p>neutropenic period</td>
<td align="center" valign="top">199 (58%)</td>
<td align="center" valign="top">200 (58.1%)</td>
</tr>
<tr>
<td align="left" valign="top">No treatment emergent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> </td>
<td align="center" valign="top">300 (87.5%)</td>
<td align="center" valign="top">301 (87.7%)</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Survival through 7 days post </p>study drug</td>
<td align="center" valign="top">318 (92.7%)</td>
<td align="center" valign="top">308 (89.5%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<p class="First">Study drug not prematurely </p>
<p>discontinued due to toxicity </p>or lack of efficacy<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="center" valign="top">294 (85.7%)</td>
<td align="center" valign="top">280 (81.4%)</td>
</tr>
</tbody>
</table>
<p>This therapeutic equivalence had no apparent relationship to the use of prestudy antifungal prophylaxis or concomitant granulocytic colony stimulating factors. </p>
<p>The incidence of mycologically confirmed and clinically diagnosed, emergent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> are presented in the following table. Am<span class="Bold">B</span>isome and amphotericin B were found to be equivalent with respect to the total number of emergent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.</p>
<a name="id_89338b2d-2ac1-43c8-89af-e85e16d1bfdc"></a><table border="single" width="511.000">
<caption><span>Empirical Therapy in Febrile Neutropenic Patients: Emergent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></span></caption>
<col width="41.1%">
<col width="25.6%">
<col width="33.3%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">AmBisome</span></td>
<td align="center" valign="top"><span class="Bold">Amphotericin B</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Number of patients receiving at least one dose of study drug</td>
<td class="Toprule" align="center" valign="top">343</td>
<td align="center" valign="top">344</td>
</tr>
<tr>
<td align="left" valign="top">Mycologically confirmed <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span></td>
<td align="center" valign="top">11 (3.2%)</td>
<td align="center" valign="top">27 (7.8%)</td>
</tr>
<tr>
<td align="left" valign="top">Clinically diagnosed <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span></td>
<td align="center" valign="top">32 (9.3%)</td>
<td align="center" valign="top">16 (4.7%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><p class="First">Total emergent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></p></td>
<td align="center" valign="top">43 (12.5%)</td>
<td align="center" valign="top">43 (12.5%)</td>
</tr>
</tbody>
</table>
<p> </p>
<p>Mycologically confirmed <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> at study-entry were cured in 8 of 11 patients in the Am<span class="Bold">B</span>isome group and 7 of 10 in the amphotericin B group. </p>
<p>Study 97-0-034, a randomized, double-blind, comparative multi-center trial, evaluated the safety of Am<span class="Bold">B</span>isome (3 and 5 mg/kg/day) compared with amphotericin B lipid complex (5 mg/kg/day) in the empirical treatment of 202 adult and 42 pediatric neutropenic patients. One hundred and sixty-six patients received Am<span class="Bold">B</span>isome (85 patients received 3 mg/kg/day and 81 received 5 mg/kg/day) and 78 patients received amphotericin B lipid complex. The study patients were febrile despite having received at least 72 hours of broad spectrum antibacterial therapy. The primary endpoint of this study was safety. The study was not designed to draw statistically meaningful conclusions related to comparative efficacy, and in fact, Abelcet is not labeled for this indication.</p>
<p>Two supportive prospective randomized, open label, comparative multi-center studies examined the efficacy of two dosages of Am<span class="Bold">B</span>isome (1 and 3 mg/kg/day) compared to amphotericin B deoxycholate (1 mg/kg/day) in the treatment of neutropenic patients with presumed <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. These patients were undergoing chemotherapy as part of a bone marrow transplant or had hematological disease. Study 104-10 enrolled adult patients (n=134). Study 104-14 enrolled pediatric patients (n=214). Both studies support the efficacy equivalence of Am<span class="Bold">B</span>isome and amphotericin B as empirical therapy in febrile neutropenic patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_070a831a-a041-401d-ab9b-0bdb51fc1b86"></a><a name="section-5.2"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span> in HIV Infected Patients.</h2>
<p class="First">Study 94-0-013, a randomized, double-blind, comparative multi-center trial, evaluated the efficacy of Am<span class="Bold">B</span>isome at doses (3 and 6 mg/kg/day) compared with amphotericin B deoxycholate (0.7 mg/kg/day) for the treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> in 266 adult and one pediatric HIV positive patients (the pediatric patient received amphotericin B deoxycholate). Of the 267 treated patients, 86 received Am<span class="Bold">B</span>isome 3 mg/kg/day, 94 received 6 mg/kg/day and 87 received amphotericin B deoxycholate; <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> was documented by a positive CSF culture at baseline in 73, 85 and 76 patients, respectively. Patients received study drug once daily for an induction period of 11 to 21 days. Following induction, all patients were switched to oral fluconazole at 400 mg/day for adults and 200 mg/day for patients less than 13 years of age to complete 10 weeks of protocol-directed therapy. For mycologically evaluable patients, defined as all randomized patients who received at least one dose of study drug, had a positive baseline CSF culture, and had at least one follow-up culture, success was evaluated at week 2 (i.e., 14 ± 4 days), and was defined as CSF culture conversion. Success rates at 2 weeks for Am<span class="Bold">B</span>isome and amphotericin B deoxycholate are summarized in the following table:</p>
<a name="id_13209afa-0480-4ace-8a0d-d58aed9fa039"></a><table border="single" width="560.000">
<caption><span>Success Rates at 2 weeks (CSF Culture Conversion) Study 94-0-013</span></caption>
<col width="28.4%">
<col width="23.6%">
<col width="23.6%">
<col width="24.5%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<span class="Bold">3 mg/kg</span>
</td>
<td class="Rrule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<span class="Bold">6 mg/kg</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B</span></p>
<span class="Bold">0.7 mg/kg</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd> 97.5% Confidence Interval for the difference between Am<span class="Bold">B</span>isome and amphotericin B success rates. A negative value is in favor of amphotericin B. A positive value is in favor of AmBisome.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="middle">Success at Week 2<br>
</td>
<td class="Rrule" align="center" valign="top">
<p class="First">35/60 (58.3%)</p>97.5% CI<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>= <br>-9.4%, +31%</td>
<td class="Rrule" align="center" valign="top">
<p class="First">36/75 (48%)</p>
<p> 97.5% CI<a href="#footnote-2" class="Sup">*</a>=</p>-18.8%, + 19.8%</td>
<td align="center" valign="top">29/61 (47.5 %)</td>
</tr></tbody>
</table>
<p>Success at 10 weeks was defined as clinical success at week 10 plus CSF culture conversion at or prior to week 10. Success rates at 10 weeks in patients with positive baseline culture for cryptococcus species are summarized in the following table and show that the efficacy of Am<span class="Bold">B</span>isome 6 mg/kg/day approximates the efficacy of the amphotericin B deoxycholate regimen. These data do not support the conclusion that AmBisome 3 mg/kg/day is comparable in efficacy to amphotericin B deoxycholate. The table also presents 10-week survival rates for patients treated in this study.</p>
<a name="id_223e927d-63f2-4d30-9c68-a4b52f669f64"></a><table border="single" width="550.000">
<caption><span>Success Rates and Survival Rates at week 10, Study 94-0-013 (see text for definitions)</span></caption>
<col width="22.5%">
<col width="23.5%">
<col width="22.0%">
<col width="32.0%">
<thead><tr class="First Last">
<td class="Botrule Rrule Toprule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<span class="Bold">3 mg/kg</span>
</td>
<td class="Rrule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<span class="Bold">6 mg/kg</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B</span></p>
<span class="Bold">0.7 mg/kg</span>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd> 97.5% Confidence Interval for the difference between Am<span class="Bold">B</span>isome and amphotericin B rates. A negative value is in favor of amphotericin B. A positive value is in favor of Am<span class="Bold">B</span>isome.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="middle">Success in patients with documented <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">27/73 (37%)</p>
<p>97.5% CI<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>=</p>-33.7%, +2.4%</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">42/85 (49%) </p>
<p>97.5% CI<a href="#footnote-3" class="Sup">*</a>=</p>
<p> -20.9%, 14.5%</p>
</td>
<td class="Botrule" align="center" valign="top">40/76 (53%)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="middle">Survival rates</td>
<td class="Rrule" align="center" valign="top">
<p class="First">74/86 (86%)</p>
<p>97.5% CI<a href="#footnote-3" class="Sup">*</a> =</p>
<p>-13.8%, +8.9%</p>
</td>
<td class="Rrule" align="center" valign="top">
<p class="First">85/94 (90%)</p>
<p>97.5% CI<a href="#footnote-3" class="Sup">*</a>= </p>
<p>-8.3%, +12.2%</p>
</td>
<td class="Botrule" align="center" valign="top">77/87 (89%)</td>
</tr>
</tbody>
</table>
<p>The incidence of infusion-related, cardiovascular and renal adverse events was lower in patients receiving Am<span class="Bold">B</span>isome compared to amphotericin B deoxycholate (see <a href="#i4i_adverse_effects_id_90a0f7f0-ba8f-4177-8aab-709885de09d6">ADVERSE REACTIONS</a> section for details); therefore, the risks and benefits (advantages and disadvantages) of the different amphotericin B formulations should be taken into consideration when selecting a patient treatment regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed059cf5-63eb-49ae-ae19-29a94475aecf"></a><a name="section-5.3"></a><p></p>
<h2>Treatment of Patients with <span class="Italics">Aspergillus </span>Species, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> Species and/or <span class="Italics">Cryptococcus</span> Species <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> Refractory to Amphotericin B Deoxycholate, or in Patients Where <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> or Unacceptable Toxicity Precludes the Use of Amphotericin B Deoxycholate </h2>
<p class="First">Am<span class="Bold">B</span>isome was evaluated in a compassionate use study in hospitalized patients with systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>. These patients either had <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> refractory to amphotericin B deoxycholate, were intolerant to the use of amphotericin B deoxycholate, or had pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Patient recruitment involved 140 infectious episodes in 133 patients, with 53 episodes evaluable for mycological response and 91 episodes evaluable for clinical outcome. Clinical success and mycological eradication occurred in some patients with documented <span class="product-label-link" type="condition" conceptid="434281" conceptname="Aspergillosis">aspergillosis</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, and <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">cryptococcosis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed2cec7f-ed96-4a6c-bc0f-c278e0d14d72"></a><a name="section-5.4"></a><p></p>
<h2>Treatment of Visceral Leishmaniasis </h2>
<p class="First">Am<span class="Bold">B</span>isome was studied in patients with visceral leishmaniasis who were infected in the Mediterranean basin with documented or presumed <span class="Italics">Leishmania infantum</span>. Clinical studies have not provided conclusive data regarding efficacy against <span class="Italics">L. donovani</span> or <span class="Italics">L. chagasi</span>. </p>
<p>Am<span class="Bold">B</span>isome achieved high rates of acute parasite clearance in immunocompetent patients when total doses of 12-30 mg/kg were administered. Most of these immunocompetent patients remained relapse-free during follow-up periods of 6 months or longer. While acute parasite clearance was achieved in most of the immunocompromised patients who received total doses of 30-40 mg/kg, the majority of these patients were observed to relapse in the 6 months following the completion of therapy. Of the 21 immunocompromised patients studied, 17 were coinfected with HIV; approximately half of the HIV infected patients had AIDS. The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no prior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy (EOT) and as overall success (clearance with no relapse) during the follow-up period (F/U) of greater than 6 months for immunocompetent and immunocompromised patients:</p>
<a name="id_8ca99d2c-82c3-495a-9e0f-3a9c6ffa7640"></a><table border="single" width="431.000">
<caption><span>AmBisome Efficacy in Visceral Leishmaniasis</span></caption>
<col width="22.3%">
<col width="19.5%">
<col width="31.1%">
<col width="27.1%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center" colspan="4" valign="top"><span class="Bold">IMMUNOCOMPETENT PATIENTS</span></td></tr>
<tr>
<td align="center" valign="top"><span class="Bold">No. of Patients</span></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Parasite (%) </span></p>
<p><span class="Bold">Clearance at EOT</span></p>
</td>
<td align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Overall Success </span></p>
<p><span class="Bold">(%) at F/U</span></p>
</td>
</tr>
<tr>
<td align="center" valign="top">87</td>
<td align="center" valign="top">86/87 (98.9)</td>
<td align="center" colspan="2" valign="top">83/86 (96.5)</td>
</tr>
<tr><td align="center" colspan="4" valign="top"><span class="Bold">IMMUNOCOMPROMISED PATIENTS</span></td></tr>
<tr>
<td align="center" valign="top"><span class="Bold">Regimen</span></td>
<td align="center" valign="top"><span class="Bold">Total Dose</span></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Parasite (%) </span></p>
<p><span class="Bold">Clearance at EOT</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Overall Success </span></p>
<p><span class="Bold">(%) at F/U</span></p>
</td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">100 mg/day </p>X 21 days</td>
<td align="center" valign="top"><p class="First">29-38.9 mg/kg</p></td>
<td align="center" valign="top">10/10 (100)</td>
<td align="center" valign="top">2/10 (20)</td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">4 mg/kg/day, days 1-5, and 10, 17, 24, 31, 38</p></td>
<td align="center" valign="top"><p class="First">40 mg/kg</p></td>
<td align="center" valign="top">8/9 (88.9)</td>
<td align="center" valign="top">0/7 (0)</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><span class="Bold">TOTAL</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">18/19 (94.7)</td>
<td align="center" valign="top">2/17 (11.8)</td>
</tr>
</tbody>
</table>
<p> </p>
<p>When followed for 6 months or more after treatment, the overall success rate among immunocompetent patients was 96.5% and the overall success rate among immunocompromised patients was 11.8% due to relapse in the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients (Lopez-Dupla, et al. <span class="Italics">J Antimicrob Chemother</span> 1993; 32: 657-659), there are no data to date documenting the efficacy or safety of repeat courses of Am<span class="Bold">B</span>isome or of maintenance therapy with this drug among immunocompromised patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_5f8f5718-3ee5-47a3-abf4-6963ec139888"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Am<span class="Bold">B</span>isome is contraindicated in those patients who have demonstrated or have known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_3b7ed80c-aefb-4438-a6bc-66107af09946"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported with amphotericin B deoxycholate and other amphotericin B-containing drugs, including Am<span class="Bold">B</span>isome. If a severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs, the infusion should be immediately discontinued and the patient should not receive further infusions of Am<span class="Bold">B</span>isome.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_74f11536-830a-4669-99e4-1b7bc46df6eb"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_90b033ec-80ac-4417-9219-fd118302a92d"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">As with any amphotericin B-containing product the drug should be administered by medically trained personnel. During the initial dosing period, patients should be under close clinical observation. Am<span class="Bold">B</span>isome has been shown to be significantly less toxic than amphotericin B deoxycholate; however, adverse events may still occur. </p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_1b3a674f-20ec-4d81-91bd-b8b4bdcf1b02"></a><a name="section-8.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Patient management should include laboratory evaluation of renal, hepatic and hematopoietic function, and serum electrolytes (particularly magnesium and potassium). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07ad1ce4-ff05-4928-a6f0-c763e331f053"></a><a name="section-8.3"></a><p></p>
<h2>Drug-Laboratory Interactions: Serum phosphate false elevation</h2>
<p class="First">False elevations of serum phosphate may occur when samples from patients receiving Am<span class="Bold">B</span>isome are analyzed using the PHOSm assay (e.g. used in Beckman Coulter analyzers including the Synchron LX20). This assay is intended for the quantitative determination of inorganic phosphorus in human serum, plasma or urine samples. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_ba59b9bd-dc3c-4f80-b997-87e31a9dade9"></a><a name="section-8.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No formal clinical studies of drug interactions have been conducted with Am<span class="Bold">B</span>isome. However, the following drugs are known to interact with amphotericin B and may interact with Am<span class="Bold">B</span>isome:</p>
<p> </p>
<p><span class="Italics">Antineoplastic Agents</span></p>
<p>Concurrent use of antineoplastic agents may enhance the potential for renal toxicity, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Antineoplastic agents should be given concomitantly with caution.</p>
<p><span class="Italics">Corticosteroids and Corticotropin (ACTH)</span></p>
<p>Concurrent use of corticosteroids and ACTH may potentiate <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> which could predispose the patient to cardiac dysfunction. If used concomitantly, serum electrolytes and cardiac function should be closely monitored.</p>
<p><span class="Italics">Digitalis Glycosides</span></p>
<p>Concurrent use may induce <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and may potentiate <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. When administered concomitantly, serum potassium levels should be closely monitored.</p>
<p><span class="Italics">Flucytosine </span></p>
<p>Concurrent use of flucytosine may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion. </p>
<p><span class="Italics">Azoles (e.g. ketoconazole, miconazole, clotrimazole, fluconazole, etc.) </span></p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> animal studies of the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B. Combination therapy should be administered with caution, especially in immunocompromised patients.</p>
<p><span class="Italics">Leukocyte Transfusions</span></p>
<p>Acute pulmonary toxicity has been reported in patients simultaneously receiving intravenous amphotericin B and leukocyte transfusions.</p>
<p><span class="Italics">Other Nephrotoxic Medications</span></p>
<p>Concurrent use of amphotericin B and other nephrotoxic medications may enhance the potential for drug-induced renal toxicity. Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications.</p>
<p><span class="Italics">Skeletal Muscle Relaxants </span></p>
<p>Amphotericin B-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may enhance the curariform effect of skeletal muscle relaxants (e.g. tubocurarine) due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. When administered concomitantly, serum potassium levels should be closely monitored.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ca42a9ac-d269-4037-8820-9a1d047ca850"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long term studies in animals have been performed to evaluate carcinogenic potential of Am<span class="Bold">B</span>isome. Am<span class="Bold">B</span>isome has not been tested to determine its mutagenic potential. A Segment I Reproductive Study in rats found an abnormal estrous cycle (prolonged diestrus) and decreased number of corpora lutea in the high dose groups (10 and 15 mg/kg, doses equivalent to human doses of 1.6 and 2.4 mg/kg based on body surface area considerations). Am<span class="Bold">B</span>isome did not affect fertility or days to copulation. There were no effects on male reproductive function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bd6d40e-ac12-4695-8dca-51815a909e51"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy Category B</h2>
<p class="First">There have been no adequate and well-controlled studies of Am<span class="Bold">B</span>isome in pregnant women. Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> have been successfully treated in pregnant women with amphotericin B deoxycholate, but the number of cases reported has been small.</p>
<p>Segment II studies in both rats and rabbits have concluded that Am<span class="Bold">B</span>isome had no teratogenic potential in these species. In rats, the maternal non-toxic dose of Am<span class="Bold">B</span>isome was estimated to be 5 mg/kg (equivalent to 0.16 to 0.8 times the recommended human clinical dose range of 1 to 5 mg/kg) and in rabbits, 3 mg/kg (equivalent to 0.2 to 1 times the recommended human clinical dose range), based on body surface area correction. Rabbits receiving the higher doses, (equivalent to 0.5 to 2 times the recommended human dose) of Am<span class="Bold">B</span>isome experienced a higher rate of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span> than did the control groups. Am<span class="Bold">B</span>isome should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks involved.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_683a5044-5802-41c1-8803-9d9c0e8a6ea7"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Many drugs are excreted in human milk. However, it is not known whether Am<span class="Bold">B</span>isome is excreted in human milk. Due to the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue nursing or whether to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_12d4d33c-de9b-453b-a710-edd8b6f09663"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Pediatric patients, age 1 month to 16 years, with presumed <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> (empirical therapy), confirmed systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> or with visceral leishmaniasis have been successfully treated with Am<span class="Bold">B</span>isome. In studies which included 302 pediatric patients administered Am<span class="Bold">B</span>isome, there was no evidence of any differences in efficacy or safety of Am<span class="Bold">B</span>isome compared to adults. Since pediatric patients have received Am<span class="Bold">B</span>isome at doses comparable to those used in adults on a per kilogram body weight basis, no dosage adjustment is required in this population. Safety and effectiveness in pediatric patients below the age of one month have not been established (See <span class="Bold">DESCRIPTION OF CLINICAL STUDIES -</span> <a href="#i4i_section_id_08b81a5f-ad43-4ad8-8743-f106075de143">Empirical Therapy in Febrile Neutropenic Patients</a> and <a href="#i4i_dosage_admin_id_dab5b8d8-3c39-4203-b40b-0c7f76d1adcd">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_c7f7914c-93f0-4a27-95fc-8e63255a6322"></a><a name="section-8.9"></a><p></p>
<h2>Elderly Patients</h2>
<p class="First">Experience with Am<span class="Bold">B</span>isome in the elderly (65 years or older) comprised 72 patients. It has not been necessary to alter the dose of Am<span class="Bold">B</span>isome for this population. As with most other drugs, elderly patients receiving Am<span class="Bold">B</span>isome should be carefully monitored. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_90a0f7f0-ba8f-4177-8aab-709885de09d6"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse events are based on the experience of 592 adult patients (295 treated with Am<span class="Bold">B</span>isome and 297 treated with amphotericin B deoxycholate) and 95 pediatric patients (48 treated with Am<span class="Bold">B</span>isome and 47 treated with amphotericin B deoxycholate) in Study 94-0-002, a randomized double-blind, multi-center study in febrile, neutropenic patients. Am<span class="Bold">B</span>isome and amphotericin B were infused over two hours.</p>
<p>The incidence of common adverse events (incidence of 10% or greater) occurring with Am<span class="Bold">B</span>isome compared to amphotericin B deoxycholate, regardless of relationship to study drug, is shown in the following table:</p>
<a name="id_6300284f-440f-4c71-86c7-c0225f70a7fb"></a><table border="single" width="478.000">
<caption><span>Empirical Therapy Study 94-0-002 Common Adverse Events</span></caption>
<col width="41.4%">
<col width="27.6%">
<col width="31.0%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Adverse Event by Body System</span></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<p><span class="Bold">n=343</span></p>
<span class="Bold">%</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B</span></p>
<p><span class="Bold">n=344</span></p>
<span class="Bold">%</span>
</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p>
<p><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p>
<p>Blood product transfusion react.</p>
<p><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></td>
<td align="center" valign="top">
<p class="First">19.8</p>
<p>13.1</p>
<p> 12</p>
<p>18.4</p>
<p>47.5</p>
<p>11.1</p>
<p>14</p>14</td>
<td align="center" valign="top">
<p class="First">21.8</p>
<p>10.8</p>
<p>7.3</p>
<p>18.6</p>
<p>75.9</p>
<p>9.3</p>
<p>12.8</p>11.3</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Cardiovascular System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center" valign="top">
<p class="First">12</p>
<p>7.9</p>
<p>14.3</p>13.4</td>
<td align="center" valign="top">
<p class="First">11.6</p>
<p>16.3</p>
<p>21.5</p>20.9</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Digestive System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">
<p class="First">30.3</p>
<p>9.9</p>
<p>39.7</p>31.8</td>
<td align="center" valign="top">
<p class="First">27.3</p>
<p>11.3</p>
<p>38.7</p>43.9</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First">Alkaline phosphatase increased</p>
<p>ALT (SGPT) increased</p>
<p>AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) increased</p>
<p><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Bilirubinemia</span></p>
<p>BUN increased</p>
<p>Creatinine increased</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Hypernatremia</span></p>
<p><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></p><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td align="center" valign="top">
<p class="First">22.2</p>
<p>14.6</p>
<p>12.8</p>
<p>18.1</p>
<p>21</p>
<p>22.4</p>
<p>14.3</p>
<p>23</p>
<p>4.1</p>
<p>12.2</p>
<p>18.4</p>
<p>42.9</p>
<p>20.4</p>14.6</td>
<td align="center" valign="top">
<p class="First">19.2</p>
<p>14</p>
<p>12.8</p>
<p>19.2</p>
<p>31.1</p>
<p>42.2</p>
<p>14.8</p>
<p>27.9</p>
<p>11</p>
<p>15.4</p>
<p>20.9</p>
<p>50.6</p>
<p>25.6</p>17.2</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p>
<p><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="top">
<p class="First">13.7</p>
<p>11.4</p>
<p>19.8</p>17.2</td>
<td align="center" valign="top">
<p class="First">11</p>
<p>13.4</p>
<p>20.9</p>14.2</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Respiratory System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
<p><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span></p>
<p><span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung disorder</span></p>
<p><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></p><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center" valign="top">
<p class="First">17.8</p>
<p>23</p>
<p>14.9</p>
<p>7.6</p>
<p>17.8</p>
<p>12.5</p>11.1</td>
<td align="center" valign="top">
<p class="First">21.8</p>
<p>29.1</p>
<p>20.1</p>
<p>14.8</p>
<p>17.4</p>
<p>9.6</p>11</td>
</tr>
<tr>
<td align="right" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Skin and Appendages</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td align="center" valign="top">
<p class="First">10.8</p>
<p>24.8</p>7</td>
<td align="center" valign="top">
<p class="First">10.2</p>
<p>24.4</p>10.8</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Urogenital System</span></td></tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">14</td>
</tr>
</tbody>
</table>
<p> </p>
<p>Am<span class="Bold">B</span>isome was well tolerated. Am<span class="Bold">B</span>isome had a lower incidence of <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and various events related to decreased kidney function as compared to amphotericin B deoxycholate.</p>
<p>In pediatric patients (16 years of age or less) in this double-blind study, Am<span class="Bold">B</span>isome compared to amphotericin B deoxycholate had a lower incidence of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (37% versus 55%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (29% versus 68%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (27% versus 55%), and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (10% versus 21%). Similar trends, although with a somewhat lower incidence, were observed in open-label, randomized Study 104-14 involving 205 febrile neutropenic pediatric patients (141 treated with Am<span class="Bold">B</span>isome and 64 treated with amphotericin B deoxycholate). Pediatric patients appear to have more tolerance than older individuals for the nephrotoxic effects of amphotericin B deoxycholate.</p>
<p>The following adverse events are based on the experience of 244 patients (202 adult and 42 pediatric patients) of whom 85 patients were treated with Am<span class="Bold">B</span>isome 3 mg/kg, 81 patients were treated with Am<span class="Bold">B</span>isome 5 mg/kg and 78 patients treated with amphotericin B lipid complex 5 mg/kg in Study 97-0-034, a randomized double-blind, multi-center study in febrile, neutropenic patients. Am<span class="Bold">B</span>isome and amphotericin B lipid complex were infused over two hours. The incidence of adverse events occurring in more than 10% of subjects in one or more arms regardless of relationship to study drug are summarized in the following table:</p>
<br><a name="id_3ae2e1d8-ea96-47e2-9391-4bb958b24854"></a><table border="single" width="603.000">
<caption><span>Empirical Therapy Study 97-0-034 Common Adverse Events </span></caption>
<col width="35.5%">
<col width="19.1%">
<col width="20.9%">
<col width="24.5%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Adverse Event by Body System</span></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<p><span class="Bold">3 mg/kg/day</span></p>
<p><span class="Bold">n=85</span></p>
<span class="Bold">%</span>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<p><span class="Bold">5 mg/kg/day</span></p>
<p><span class="Bold">n=81</span></p>
<span class="Bold">%</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B Lipid Complex</span></p>
<p><span class="Bold">5 mg/kg/day</span></p>
<p><span class="Bold">n=78</span></p>
<span class="Bold">%</span>
</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></p>
<p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p><span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">Transfusion reaction</span></td>
<td align="center" valign="top">
<p class="First">12.9</p>
<p>8.2</p>
<p>40</p>
<p>12.9</p>10.6</td>
<td align="center" valign="top">
<p class="First">9.9</p>
<p>6.2</p>
<p>48.1</p>
<p>7.4</p>8.6</td>
<td align="center" valign="top">
<p class="First">11.5</p>
<p>11.5</p>
<p>89.7</p>
<p>11.5</p>5.1</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Cardiovascular System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center" valign="top">
<p class="First">8.2</p>
<p>10.6</p>
<p>10.6</p>9.4</td>
<td align="center" valign="top">
<p class="First">11.1</p>
<p>19.8</p>
<p>7.4</p>18.5</td>
<td align="center" valign="top">
<p class="First">6.4</p>
<p>23.1</p>
<p>19.2</p>23.1</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Digestive System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">
<p class="First">15.3</p>
<p>25.9</p>22.4</td>
<td align="center" valign="top">
<p class="First">17.3</p>
<p>29.6</p>25.9</td>
<td align="center" valign="top">
<p class="First">14.1</p>
<p>37.2</p>30.8</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First">Alkaline phosphatase increased</p>
<p><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Bilirubinemia</span></p>
<p>BUN increased</p>
<p>Creatinine increased</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Hypervolemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></p><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function tests abnormal</span></td>
<td align="center" valign="top">
<p class="First">7.1</p>
<p>16.5</p>
<p>20</p>
<p>20</p>
<p>12.9</p>
<p>8.2</p>
<p>8.2</p>
<p>10.6</p>
<p>37.6</p>
<p>15.3</p>10.6</td>
<td align="center" valign="top">
<p class="First">8.6</p>
<p>11.1</p>
<p>18.5</p>
<p>18.5</p>
<p>12.3</p>
<p>8.6</p>
<p>11.1</p>
<p>4.9</p>
<p>43.2</p>
<p>25.9</p>7.4</td>
<td align="center" valign="top">
<p class="First">12.8</p>
<p>11.5</p>
<p>28.2</p>
<p>48.7</p>
<p>12.8</p>
<p>14.1</p>
<p>14.1</p>
<p>5.1</p>
<p>39.7</p>
<p>15.4</p>11.5</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p>
<p><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">
<p class="First">10.6</p>
<p>12.9</p>9.4</td>
<td align="center" valign="top">
<p class="First">7.4</p>
<p>8.6</p>17.3</td>
<td align="center" valign="top">
<p class="First">9</p>
<p>3.8</p>10.3</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Respiratory System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p>
<p><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span></p><span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Lung disorder</span></td>
<td align="center" valign="top">
<p class="First">17.6</p>
<p>10.6</p>
<p>7.1</p>14.1</td>
<td align="center" valign="top">
<p class="First">22.2</p>
<p>8.6</p>
<p>6.2</p>13.6</td>
<td align="center" valign="top">
<p class="First">23.1</p>
<p>14.1</p>
<p>20.5</p>15.4</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Skin and Appendages</span></td></tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">23.5</td>
<td align="center" valign="top">22.2</td>
<td align="center" valign="top">14.1</td>
</tr>
</tbody>
</table>
<p> </p>
<p>The following adverse events are based on the experience of 267 patients (266 adult patients and 1 pediatric patient) of whom 86 patients were treated with Am<span class="Bold">B</span>isome 3 mg/kg, 94 patients were treated with Am<span class="Bold">B</span>isome 6 mg/kg and 87 patients treated with amphotericin B deoxycholate 0.7 mg/kg in Study 94-0-013 a randomized, double-blind, comparative multi-center trial, in the treatment of <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> in HIV positive patients. The incidence of adverse events occurring in more than 10% of subjects in one or more arms regardless of relationship to study drug are summarized in the following table:</p>
<a name="id_25f881c6-6f51-4216-85b4-00d4e14e8506"></a><table border="single" width="594.000">
<caption><span><span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal Meningitis</span> Therapy Study 94-0-013 Common Adverse Events </span></caption>
<col width="37.0%">
<col width="15.3%">
<col width="17.3%">
<col width="30.3%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Adverse Event by Body System</span></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<p><span class="Bold">3 mg/kg/day</span></p>
<p><span class="Bold">n=86</span></p>
<span class="Bold">%</span>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<p><span class="Bold">6 mg/kg/day</span></p>
<p><span class="Bold">n=94</span></p>
<span class="Bold">%</span>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B </span></p>
<p><span class="Bold">0.7 mg/kg/day</span></p>
<p><span class="Bold">n=87</span></p>
<span class="Bold">%</span>
</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p>Procedural Complication</td>
<td align="center" valign="top">
<p class="First">7</p>
<p>12.8</p>8.1</td>
<td align="center" valign="top">
<p class="First">7.4</p>
<p>11.7</p>9.6</td>
<td align="center" valign="top">
<p class="First">10.3</p>
<p>6.9</p>10.3</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Cardiovascular System</span></td></tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></td>
<td align="center" valign="top">9.3</td>
<td align="center" valign="top">10.6</td>
<td align="center" valign="top">25.3</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Digestive System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">
<p class="First">14</p>
<p>15.1</p>
<p>10.5</p>
<p>16.3</p>10.5</td>
<td align="center" valign="top">
<p class="First">9.6</p>
<p>14.9</p>
<p>16</p>
<p>21.3</p>21.3</td>
<td align="center" valign="top">
<p class="First">11.5</p>
<p>20.7</p>
<p>10.3</p>
<p>25.3</p>20.7</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Hemic and Lymphatic System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center" valign="top">
<p class="First">26.7</p>
<p>15.1</p>5.8</td>
<td align="center" valign="top">
<p class="First">47.9</p>
<p>17</p>12.8</td>
<td align="center" valign="top">
<p class="First">43.7</p>
<p>17.2</p>6.9</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Bilirubinemia</span></p>
<p>BUN increased</p>
<p>Creatinine increased</p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></p><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver Function Tests Abnormal</span></td>
<td align="center" valign="top">
<p class="First">0</p>
<p>9.3</p>
<p>18.6</p>
<p>9.3</p>
<p>12.8</p>
<p>31.4</p>
<p>29.1</p>
<p>11.6</p>12.8</td>
<td align="center" valign="top">
<p class="First">8.5</p>
<p>7.4</p>
<p>39.4</p>
<p>12.8</p>
<p>17</p>
<p>51.1</p>
<p>48.9</p>
<p>8.5</p>4.3</td>
<td align="center" valign="top">
<p class="First">12.6</p>
<p>10.3</p>
<p>43.7</p>
<p>17.2</p>
<p>13.8</p>
<p>48.3</p>
<p>40.2</p>
<p>9.2</p>9.2</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="top">
<p class="First">7</p>22.1</td>
<td align="center" valign="top">
<p class="First">8.5</p>17</td>
<td align="center" valign="top">
<p class="First">10.3</p>20.7</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Respiratory System</span></td></tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span></td>
<td align="center" valign="top">8.1</td>
<td align="center" valign="top">2.1</td>
<td align="center" valign="top">10.3</td>
</tr>
<tr><td align="left" colspan="4" valign="top"><span class="Bold">Skin and Appendages</span></td></tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">4.7</td>
<td align="center" valign="top">11.7</td>
<td align="center" valign="top">4.6</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3350af73-cdae-42db-b94a-82ce17aac13d"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">Infusion Related Reactions</span></h2>
<p class="First">In Study 94-0-002, the large, double-blind study of pediatric and adult febrile neutropenic patients, no premedication to prevent <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reaction</span> was administered prior to the first dose of study drug (Day 1). Am<span class="Bold">B</span>isome-treated patients had a lower incidence of infusion related <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (17% versus 44%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> (18% versus 54%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6% versus 8%) on Day 1 as compared to amphotericin B deoxycholate-treated patients.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reactions</span> on Day 1 in pediatric and adult patients is summarized in the following table:</p>
<a name="id_c5b4688e-cda3-4468-b96f-66e339272984"></a><table border="single" width="543.000">
<caption><span>Incidence of Day 1 <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">Infusion Related Reactions</span> (IRR) By Patient Age</span></caption>
<col width="15.8%">
<col width="15.3%">
<col width="22.5%">
<col width="16.9%">
<col width="29.5%">
<thead>
<tr class="First Toprule">
<td align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Pediatric Patients</span></p>
<span class="Bold">(≤16 years of age)</span>
</td>
<td align="center" colspan="3" valign="top">
<p class="First"><span class="Bold">Adult Patients</span></p>
<span class="Bold">(&gt; 16 years of age)</span>
</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">AmBisome</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Amphotericin B</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">AmBisome</span></td>
<td align="center" valign="top"><span class="Bold">Amphotericin B</span></td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Day 1 body temperature increased above the temperature taken within 1 hour prior to infusion (preinfusion temperature) or above the lowest infusion value (no preinfusion temperature recorded). </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">Total number of patients receiving at least one dose of study drug</span></td>
<td class="Toprule" align="center" valign="top">48</td>
<td class="Toprule" align="center" valign="top">47</td>
<td class="Toprule" align="center" valign="top">295</td>
<td align="center" valign="top">297</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span><span class="Bold">Increase </span>≥1.0<span class="Sup">o</span>C</td>
<td align="center" valign="top">6 (13%)</td>
<td align="center" valign="top">22 (47%)</td>
<td align="center" valign="top">52 (18%)</td>
<td align="center" valign="top">128 (43%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></span></td>
<td align="center" valign="top">4 (8%)</td>
<td align="center" valign="top">22 (47%)</td>
<td align="center" valign="top">59 (20%)</td>
<td align="center" valign="top">165 (56%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></span></td>
<td align="center" valign="top">4 (8%)</td>
<td align="center" valign="top">4 (9%)</td>
<td align="center" valign="top">38 (13%)</td>
<td align="center" valign="top">31 (10%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></span></td>
<td align="center" valign="top">2 (4%)</td>
<td align="center" valign="top">7 (15%)</td>
<td align="center" valign="top">19 (6%)</td>
<td align="center" valign="top">21 (7%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="Bold">Patients with other reactions</span></td>
<td align="center" valign="top">10 (21%)</td>
<td align="center" valign="top">13 (28%)</td>
<td align="center" valign="top">47 (16%)</td>
<td align="center" valign="top">69 (23%)</td>
</tr>
</tbody>
</table>
<p>Cardiorespiratory events, except for <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>), during all study drug infusions were more frequent in amphotericin B-treated patients as summarized in the following table:</p>
<a name="id_d940d802-0a8f-4e80-8249-9b693830a6e8"></a><table border="single" width="511.000">
<caption><span>Incidence of Infusion Related Cardiorespiratory Events</span></caption>
<col width="27.8%">
<col width="32.5%">
<col width="39.7%">
<thead><tr class="Botrule First Last">
<td align="center" valign="top"><span class="Bold">Event</span></td>
<td class="Toprule" align="center" valign="top">
<p class="First"><span class="Bold">AmBisome</span></p>
<p><span class="Bold">n=343</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B</span> </p>
<p><span class="Bold">n=344</span></p>
</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Toprule" align="center" valign="top">12 (3.5%)</td>
<td align="center" valign="top">28 (8.1%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center" valign="top">8 (2.3%)</td>
<td align="center" valign="top">43 (12.5%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center" valign="top">8 (2.3%)</td>
<td align="center" valign="top">39 (11.3%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span></td>
<td align="center" valign="top">18 (5.2%)</td>
<td align="center" valign="top">2 (0.6%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center" valign="top">16 (4.7%)</td>
<td align="center" valign="top">25 (7.3%)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span></td>
<td align="center" valign="top">4 (1.2%)</td>
<td align="center" valign="top">17 (4.9%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span></td>
<td align="center" valign="top">1 (0.3%)</td>
<td align="center" valign="top">22 (6.4%)</td>
</tr>
</tbody>
</table>
<p>The percentage of patients who received drugs either for the treatment or prevention of <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reactions</span> (e.g., acetaminophen, diphenhydramine, meperidine and hydrocortisone) was lower in Am<span class="Bold">B</span>isome-treated patients compared with amphotericin B deoxycholate-treated patients.</p>
<p>In the empirical therapy study 97-0-034, on Day 1, where no premedication was administered, the overall incidence of infusion related events of <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> was significantly lower for patients administered Am<span class="Bold">B</span>isome compared with amphotericin B lipid complex. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> were significantly lower for each Am<span class="Bold">B</span>isome group compared with the amphotericin B lipid complex group. The infusion related event <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> was reported for 11.5% of amphotericin B lipid complex-treated patients compared with 0% of patients administered 3 mg/kg per day Am<span class="Bold">B</span>isome and 1.2% of patients treated with 5 mg/kg per day Am<span class="Bold">B</span>isome.</p>
<br><a name="id_5e0672c5-f901-463f-bc72-bbc126da286d"></a><table border="single" width="627.000">
<caption><span>Incidence of Day 1 <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">Infusion Related Reactions</span> (IRR) <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span> Empirical Therapy Study 97-0-034 </span></caption>
<col width="28.5%">
<col width="17.1%">
<col width="15.8%">
<col width="14.8%">
<col width="23.8%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" colspan="3" valign="top">
<span class="Bold">AmBisome</span><p class="First"> </p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B lipid complex</span></p>
<span class="Bold">5 mg/kg/day</span>
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"><span class="Bold">3 mg/kg/day</span></td>
<td align="center" valign="top"><span class="Bold">5 mg/kg/day</span></td>
<td align="center" valign="top"><span class="Bold">BOTH</span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Total number of patients</td>
<td align="center" valign="top">85</td>
<td align="center" valign="top">81</td>
<td align="center" valign="top">166</td>
<td align="center" valign="top">78</td>
</tr>
<tr>
<td align="left" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span> (Day1)</td>
<td align="center" valign="top">16 (18.8%)</td>
<td align="center" valign="top">19 (23.5%)</td>
<td align="center" valign="top">35 (21.1%)</td>
<td align="center" valign="top">62 (79.5%)</td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Patients with other notable reactions:</p></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>(≥1<span class="Sup">o</span>C increase in temperature)</p></td>
<td align="center" valign="top"><p class="First">20 (23.5%)</p></td>
<td align="center" valign="top"><p class="First">16 (19.8%)</p></td>
<td align="center" valign="top"><p class="First">36 (21.7%)</p></td>
<td align="center" valign="top"><p class="First">45 (57.7%)</p></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span></td>
<td align="center" valign="top">
<p class="First">9 (10.6%)</p>
<p>5 (5.9%)</p>
<p>4 (4.7%)</p>
<p>2 (2.4%)</p>
<p>4 (4.7%)</p>0</td>
<td align="center" valign="top">
<p class="First">7 (8.6%)</p>
<p>5 (6.2%)</p>
<p>7 (8.6%)</p>
<p>8 (9.9%)</p>
<p>8 (9.9%)</p>1 (1.2%)</td>
<td align="center" valign="top">
<p class="First">16 (9.6%)</p>
<p>10 (6%)</p>
<p>11 (6.6%)</p>
<p>10 (6%)</p>
<p>12 (7.2%)</p>1 (&lt;1%)</td>
<td align="center" valign="top">
<p class="First">9 (11.5%)</p>
<p>11 (14.1%)</p>
<p>12 (15.4%)</p>
<p>14 (17.9%)</p>
<p>8 (10.3%)</p>9 (11.5%)</td>
</tr>
</tbody>
</table>
<p>Day 1 body temperature increased above the temperature taken within 1 hour prior to infusion (preinfusion temperature) or above the lowest infusion value (no preinfusion temperature recorded).</p>
<p>Patients were not administered premedications to prevent <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reactions</span> prior to the Day 1 study drug infusion.</p>
<p>In Study 94-0-013, a randomized double-blind multicenter trial comparing Am<span class="Bold">B</span>isome and amphotericin B deoxycholate as initial therapy for <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span>, premedications to prevent <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reactions</span> were permitted. Am<span class="Bold">B</span>isome treated patients had a lower incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, chill/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> and respiratory adverse events as summarized in the following table:</p>
<a name="id_f6c0a2dd-7ae0-49cd-afc8-f0274d4937a0"></a><table border="single" width="473.000">
<caption><span>Incidence of Infusion-Related Reactions Study 94-0-013</span></caption>
<col width="33.8%">
<col width="17.3%">
<col width="17.3%">
<col width="31.5%">
<thead><tr class="Botrule First Last">
<td align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top">Am<span class="Bold">B</span>isome 3 mg/kg</td>
<td class="Toprule" align="center" valign="top">Am<span class="Bold">B</span>isome 6 mg/kg</td>
<td align="center" valign="top">Amphotericin B</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Total number of patients receiving at least one dose of study drug</td>
<td class="Toprule" align="center" valign="top">86</td>
<td class="Toprule" align="center" valign="top">94</td>
<td align="center" valign="top">87</td>
</tr>
<tr>
<td align="left" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> increase of &gt;1ºC</td>
<td align="center" valign="top">6 (7%)</td>
<td align="center" valign="top">8 (9%)</td>
<td align="center" valign="top">24 (28%)</td>
</tr>
<tr>
<td align="left" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></td>
<td align="center" valign="top">5 (6%)</td>
<td align="center" valign="top">8 (9%)</td>
<td align="center" valign="top">42 (48%)</td>
</tr>
<tr>
<td align="left" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td align="center" valign="top">11 (13%)</td>
<td align="center" valign="top">13 (14%)</td>
<td align="center" valign="top">18 (20%)</td>
</tr>
<tr>
<td align="left" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td align="center" valign="top">14 (16%)</td>
<td align="center" valign="top">13 (14%)</td>
<td align="center" valign="top">16 (18%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Respiratory adverse events</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">1 (1%)</td>
<td align="center" valign="top">8 (9%)</td>
</tr>
</tbody>
</table>
<p> </p>
<p>There have been a few reports of <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> with or without <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> associated with Am<span class="Bold">B</span>isome administration; on occasion this has been severe. Where these symptoms were noted, the reaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. The symptoms do not occur with every dose and usually do not recur on subsequent administrations when the infusion rate is slowed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3dfef49f-936b-4f41-b89a-bc43c9490a6d"></a><a name="section-9.2"></a><p></p>
<h2>Toxicity and Discontinuation of Dosing</h2>
<p class="First">In Study 94-0-002, a significantly lower incidence of grade 3 or 4 toxicity was observed in the Am<span class="Bold">B</span>isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity or discontinuation of study drug due to an <span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">infusion related reaction</span> compared with those administered Am<span class="Bold">B</span>isome.</p>
<p>In empirical therapy study 97-0-034, a greater proportion of patients in the amphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am<span class="Bold">B</span>isome groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68516bf0-8edd-4087-a187-7b29ac26ca2d"></a><a name="section-9.3"></a><p></p>
<h2>Less Common Adverse Events</h2>
<p class="First">The following adverse events also have been reported in 2% to 10% of Am<span class="Bold">B</span>isome-treated patients receiving chemotherapy or bone marrow transplantation, or had <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> in six comparative, clinical trials:</p>
<p><span class="Bold"><span class="Italics">Body as a Whole</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4101555" conceptname="Cell-mediated immune reaction">cell mediated immunological reaction</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="443216" conceptname="Graft versus host disease">graft versus host disease</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, and procedural complication<span class="Bold">.</span></p>
<p><span class="Bold"><span class="Italics">Cardiovascular</span></span><span class="Bold"><span class="Italics"> System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>, <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorder</span>, and <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> (<span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>).</p>
<p><span class="Bold"><span class="Italics">Digestive System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>/nose, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, gum/<span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">oral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, and veno-occlusive liver disease<span class="Bold">.</span></p>
<p><span class="Bold"><span class="Italics">Hemic &amp; Lymphatic System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorder</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechia</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> decreased, <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin increased</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold"><span class="Italics">Metabolic &amp; Nutritional Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span>, amylase increased, <span class="product-label-link" type="condition" conceptid="4253927" conceptname="Hyperchloremia">hyperchloremia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">hypermagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, lactate dehydrogenase increased, nonprotein nitrogen (NPN) increased, and <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, thinking abnormality, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Bold"><span class="Italics">Respiratory System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">atelectasis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
<p><span class="Bold"><span class="Italics">Skin &amp; Appendages</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="4319318" conceptname="Injection site inflammation">injection site inflammation</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>.</p>
<p><span class="Bold"><span class="Italics">Special Senses</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, and <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital System</span></span></p>
<p>Abnormal renal function, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute kidney failure</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, and <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9bd40f42-d6a3-4132-8a7b-91112eac7048"></a><a name="section-9.4"></a><p></p>
<h2>Post-marketing Experience</h2>
<p class="First">The following infrequent adverse experiences have been reported in post-marketing surveillance, in addition to those mentioned above: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>/<span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>, and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12294a7f-e6e3-4f39-bfe5-90acd18b7268"></a><a name="section-9.5"></a><p></p>
<h2>Clinical Laboratory Values</h2>
<p class="First">The effect of Am<span class="Bold">B</span>isome on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study 94-0-002. The frequency and magnitude of hepatic test abnormalities were similar in the Am<span class="Bold">B</span>isome and amphotericin B groups. <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> was defined as creatinine values increasing 100% or more over pretreatment levels in pediatric patients, and creatinine values increasing 100% or more over pretreatment levels in adult patients provided the peak creatinine concentration was &gt;1.2 mg/dL. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> was defined as potassium levels ≤2.5 mmol/L any time during treatment.</p>
<p>Incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, mean peak serum creatinine concentration, mean change from baseline in serum creatinine, and, incidence of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in the double-blind randomized study were lower in the Am<span class="Bold">B</span>isome group as summarized in the following table:</p>
<a name="id_ce35fa6d-7a50-444a-99d1-ed9123adfd60"></a><table border="single" width="500.000">
<caption><span>Study 94-0-002 Laboratory Evidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></caption>
<col width="42.0%">
<col width="25.0%">
<col width="33.0%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">AmBisome</span></td>
<td align="center" valign="top"><span class="Bold">Amphotericin B</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Total number of patients receiving at least one dose of study drug</td>
<td class="Toprule" align="center" valign="top">343</td>
<td align="center" valign="top">344</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></td>
<td align="center" valign="top">64 (18.7%)</td>
<td align="center" valign="top">116 (33.7%)</td>
</tr>
<tr>
<td align="left" valign="top">Mean peak creatinine</td>
<td align="center" valign="top">1.24 mg/dL</td>
<td align="center" valign="top">1.52 mg/dL</td>
</tr>
<tr>
<td align="left" valign="top">Mean change from baseline in creatinine</td>
<td align="center" valign="top">0.48 mg/dL</td>
<td align="center" valign="top">0.77 mg/dL</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center" valign="top">23 (6.7%)</td>
<td align="center" valign="top">40 (11.6%)</td>
</tr>
</tbody>
</table>
<p> </p>
<p>The effect of Am<span class="Bold">B</span>isome (3 mg/kg/day) vs. amphotericin B (0.6 mg/kg/day) on renal function in adult patients enrolled in this study is illustrated in the following figure:</p>
<div class="Figure"><img alt="graph1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a&amp;name=3ab7fe3b-149e-4ff5-826a-1e23a6d39b55-03.jpg"></div>
<p>In empirical therapy study 97-0-034, the incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> as measured by increases of serum creatinine from baseline was significantly lower for patients administered Am<span class="Bold">B</span>isome (individual dose groups and combined) compared with amphotericin B lipid complex. </p>
<p><span class="Bold">Incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></span></p>
<a name="id_18d837e6-deee-454c-ba21-38b48f075141"></a><table border="single" width="561.000">
<caption><span>Empirical Therapy Study 97-0-034 </span></caption>
<col width="27.6%">
<col width="16.2%">
<col width="14.6%">
<col width="14.6%">
<col width="26.9%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" colspan="3" valign="top">
<span class="Bold">AmBisome</span><p class="First"> </p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Amphotericin B lipid complex</span></p>
<span class="Bold">5 mg/kg/day</span>
</td>
</tr>
<tr>
<td align="center" valign="top"> </td>
<td align="center" valign="top"><span class="Bold">3 mg/kg/day</span></td>
<td align="center" valign="top"><span class="Bold">5 mg/kg/day</span></td>
<td align="center" valign="top"><span class="Bold">BOTH</span></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Total number of patients</span></td>
<td align="center" valign="top">85</td>
<td align="center" valign="top">81</td>
<td align="center" valign="top">166</td>
<td align="center" valign="top">78</td>
</tr>
<tr><td align="center" colspan="5" valign="top"><span class="Bold">Number with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span></span></td></tr>
<tr>
<td align="left" valign="top"><span class="Bold">1.5X baseline serum creatinine value</span></td>
<td align="center" valign="top">25 (29.4%)</td>
<td align="center" valign="top">21 (25.9%)</td>
<td align="center" valign="top">46 (27.7%)</td>
<td align="center" valign="top">49 (62.8%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="Bold">2X baseline serum creatinine value</span></td>
<td align="center" valign="top">12 (14.1%)</td>
<td align="center" valign="top">12 (14.8%)</td>
<td align="center" valign="top">24 (14.5%)</td>
<td align="center" valign="top">33 (42.3%)</td>
</tr>
</tbody>
</table>
<p>The following graph shows the average serum creatinine concentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, especially those with elevated (greater than 1.7 mg/dL) pretreatment creatinine concentrations.</p>
<div class="Figure"><img alt="graph2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a&amp;name=3ab7fe3b-149e-4ff5-826a-1e23a6d39b55-04.jpg"></div>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> in Study 94-0-013, comparative trial in <span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">cryptococcal meningitis</span> was lower in the Am<span class="Bold">B</span>isome groups as shown in the following table:</p>
<br><a name="id_1adaa8f9-a984-4f7e-abf7-a771f41ad8f2"></a><table border="single" width="489.000">
<caption><span>Laboratory Evidence of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> Study 94-0-013</span></caption>
<col width="25.8%">
<col width="21.7%">
<col width="21.3%">
<col width="31.3%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"></td>
<td class="Toprule" align="center" valign="top">
<p class="First">Am<span class="Bold">B</span>isome </p>
<p>3 mg/kg</p>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First">Am<span class="Bold">B</span>isome </p>
<p>6 mg/kg</p>
</td>
<td align="center" valign="top">Amphotericin B</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Total number of patients receiving at least one dose of study drug</td>
<td class="Toprule" align="center" valign="top">86</td>
<td class="Toprule" align="center" valign="top">94</td>
<td align="center" valign="top">87</td>
</tr>
<tr><td align="center" colspan="4" valign="top">
<p class="First">Number with <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></p> (%)</td></tr>
<tr>
<td align="left" valign="top">1.5X baseline serum creatinine</td>
<td align="center" valign="top">30 (35%)</td>
<td align="center" valign="top">44 (47%)</td>
<td align="center" valign="top">52 (60%)</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">2 X baseline serum creatinine</td>
<td align="center" valign="top">12 (14%)</td>
<td align="center" valign="top">20 (21%)</td>
<td align="center" valign="top">29 (33%)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_da1d7cd6-0e6b-4fb6-ae5a-d894e4b9147f"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxicity of Am<span class="Bold">B</span>isome due to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has not been defined. Repeated daily doses up to 10 mg/kg in pediatric patients and 15 mg/kg in adult patients have been administered in clinical trials with no reported dose-related toxicity. </p>
<p><span class="Bold">Management</span></p>
<p>If overdosage should occur, cease administration immediately. Symptomatic supportive measures should be instituted. Particular attention should be given to monitoring renal function. Hemodialysis or peritoneal dialysis do not appear to significantly affect the elimination of Am<span class="Bold">B</span>isome.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_dab5b8d8-3c39-4203-b40b-0c7f76d1adcd"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Am<span class="Bold">B</span>isome should be administered by intravenous infusion, using a controlled infusion device, over a period of approximately 120 minutes. </p>
<p>An in-line membrane filter may be used for the intravenous infusion of Am<span class="Bold">B</span>isome; provided <span class="Bold">THE MEAN PORE DIAMETER OF THE FILTER IS NOT LESS THAN 1.0 MICRON</span>.</p>
<p><span class="Bold">NOTE: An existing intravenous line must be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with 5% Dextrose Injection prior to infusion of AmBisome. If this is not feasible, AmBisome must be administered through a separate line.</span></p>
<p>Infusion time may be reduced to approximately 60 minutes in patients in whom the treatment is well-tolerated. If the patient experiences <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> during infusion, the duration of infusion may be increased. </p>
<p>The recommended initial dose of Am<span class="Bold">B</span>isome for each indication for adult and pediatric patients is as follows: </p>
<a name="id_0525b064-2d2a-4329-a017-a75b1cdd42b8"></a><table border="single" width="451.000">
<col width="53.4%">
<col width="46.6%">
<thead><tr class="Botrule First Last">
<td align="center" valign="top"><span class="Bold">Indication</span></td>
<td align="center" valign="top"><span class="Bold">Dose (mg/kg/day)</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Empirical therapy </td>
<td align="center" valign="top">3 </td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>:</p>
<p><span class="Italics">Aspergillus</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span></p>
<p><span class="Italics">Cryptococcus</span></p>
</td>
<td align="center" valign="top">3-5<br>
</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432310" conceptname="Cryptococcal meningitis">Cryptococcal meningitis</span> in HIV infected patients (see <a href="#i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce">DESCRIPTION OF CLINICAL STUDIES</a>)</td>
<td align="center" valign="top">6</td>
</tr>
</tbody>
</table>
<p> </p>
<p>Dosing and rate of infusion should be individualized to the needs of the specific patient to ensure maximum efficacy while minimizing systemic toxicities or adverse events.</p>
<p>Doses recommended for visceral leishmaniasis are presented below:</p>
<a name="id_3baa26b0-3777-41b1-a71b-87f27fcd1a76"></a><table border="single" width="451.000">
<col width="47.7%">
<col width="52.3%">
<thead><tr class="Botrule First Last">
<td align="center" valign="top"><span class="Bold">Visceral Leishmaniasis</span></td>
<td align="center" valign="top"><span class="Bold">Dose (mg/kg/day)</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="center" valign="top">Immunocompetent patients</td>
<td align="center" valign="top">
<p class="First">3 (days 1-5) and </p>3 on days 14, 21</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top">Immunocompromised patients</td>
<td align="center" valign="top">
<p class="First">4 (days 1-5) and</p> 4 on days 10, 17, 24, 31, 38</td>
</tr>
</tbody>
</table>
<p><span class="Bold">For immunocompetent patients</span> who do not achieve parasitic clearance with the recommended dose, a repeat course of therapy may be useful.</p>
<p><span class="Bold">For immunocompromised patients </span>who do not clear parasites or who experience relapses, expert advice regarding further treatment is recommended. For additional information see <a href="#i4i_clinical_studies_id_0f18fd72-5138-4119-bae6-5b47dc785fce">DESCRIPTION OF CLINICAL STUDIES</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00b50b09-0125-48b2-8450-94131640d566"></a><a name="section-11.1"></a><p></p>
<h2>Directions for Reconstitution, Filtration and Dilution</h2>
<p class="First"><span class="Bold">Read This Entire Section Carefully Before Beginning Reconstitution</span></p>
<p>Am<span class="Bold">B</span>isome <span class="Bold">must</span> be reconstituted using Sterile Water for Injection, USP (without a bacteriostatic agent). Vials of Am<span class="Bold">B</span>isome containing 50 mg of amphotericin B are prepared as follows:</p>
<p> </p>
<p><span class="Italics">Reconstitution</span><br></p>
<p>1. Aseptically add 12 mL of Sterile Water for Injection, USP to each Am<span class="Bold">B</span>isome vial to yield a preparation containing 4 mg amphotericin B/mL.</p>
<p><span class="Bold">CAUTION: DO NOT RECONSTITUTE WITH SALINE OR ADD SALINE TO THE RECONSTITUTED CONCENTRATION, OR MIX WITH OTHER DRUGS. </span>The use of any solution other than those recommended, or the presence of a bacteriostatic agent in the solution, may cause precipitation of Am<span class="Bold">B</span>isome.</p>
<p>2.<span class="Bold"> Immediately after the addition of water, SHAKE THE VIAL VIGOROUSLY</span> for 30 seconds to completely disperse the Am<span class="Bold">B</span>isome. Am<span class="Bold">B</span>isome forms a yellow, translucent suspension. Visually inspect the vial for particulate matter and continue <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> until completely dispersed.<br></p>
<p><span class="Italics">Filtration and Dilution<br></span></p>
<p>3. Calculate the amount of reconstituted (4 mg/mL) Am<span class="Bold">B</span>isome to be further diluted. </p>
<p>4. Withdraw this amount of reconstituted Am<span class="Bold">B</span>isome into a sterile syringe.</p>
<p>5. Attach the 5-micron filter, provided, to the syringe. Inject the syringe contents through the filter, into the appropriate amount of 5% Dextrose Injection. (Use only one filter per vial of Am<span class="Bold">B</span>isome.)</p>
<p>6. Am<span class="Bold">B</span>isome must be diluted with 5% Dextrose Injection to a final concentration of 1 to 2 mg/mL prior to administration. Lower concentrations (0.2 to 0.5 mg/mL) may be appropriate for infants and small children to provide sufficient volume for infusion. <span class="Bold">DISCARD PARTIALLY USED VIALS</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7465a9f4-7359-4a35-a1f2-2986f17c1437"></a><a name="section-12"></a><p></p>
<h1>STORAGE OF AMBISOME</h1>
<p class="First">Unopened vials of lyophilized material are to be stored at temperatures up to 25° C (77° F). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8701e3a-d7cd-43ac-9e55-cd04d533a1bb"></a><a name="section-12.1"></a><p></p>
<h2>Storage of Reconstituted Product Concentrate</h2>
<p class="First">The reconstituted product concentrate may be stored for up to 24 hours at 2º-8º C (36º-46º F) following reconstitution with Sterile Water for Injection, USP. Do not freeze.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f428ace0-488c-4076-bd03-13484562fd2f"></a><a name="section-12.2"></a><p></p>
<h2>Storage of Diluted Product</h2>
<p class="First">Injection of Am<span class="Bold">B</span>isome should commence within 6 hours of dilution with 5% Dextrose Injection. </p>
<p>As with all parenteral drug products, the reconstituted Am<span class="Bold">B</span>isome should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use material if there is any evidence of precipitation or foreign matter. Aseptic technique must be strictly observed in all handling since no preservative or bacteriostatic agent is present in Am<span class="Bold">B</span>isome or in the materials specified for reconstitution and dilution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_14b7ee02-5d95-44f2-9d5b-ebc7d76e6f62"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Am<span class="Bold">B</span>isome for Injection is available as single vial cartons (equivalent to 50mg amphotericin B) and in packs of ten individual vial cartons</p>
<p>(NDC 0469-3051-30).</p>
<p>Each carton contains one pre-packaged, disposable sterile 5 micron filter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c91ed18-cfd1-49f3-b0be-729862a98bca"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">References</span></h1>
<ol>
<li>CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI). METHOD FOR BROTH DILUTION ANTIFUNGAL SUSCEPTIBILITY TESTING OF YEASTS; APPROVED STANDARD -  3RD EDITION. CLSI DOCUMENT M27- A3. CLSI, 940 WEST VALLEY RD. SUITE 1400, WAYNE, PA 19087-1898, 2008.</li>
<li> CLSI. REFERENCE METHOD FOR BROTH DILUTION ANTIFUNGAL SUSCEPTIBILITY TESTING OF YEAST; 3RD INFORMATIONAL SUPPLEMENT. CLSI DOCUMENT M27-S3, 2008</li>
<li>  CLSI. METHOD FOR ANTIFUNGAL DISK DIFFUSION SUSCEPTIBILITY TESTING OF YEASTS; APPROVED GUIDELINE- 2ND EDITION. CLSI DOCUMENT M44-A2, 2009.</li>
<li>  CLSI REFERENCE METHOD FOR BROTH DILUTION ANTIFUNGAL SUSCEPTIBILITY TESTING OF FILAMENTOUS FUNGI; APPROVED STANDARD – 2ND EDITION. CLSI DOCUMENT M38-A2, 2008.</li>
<li>  CLSI. METHOD FOR ANTIFUNGAL DISK DIFFUSION SUSCEPTIBILITY TESTING OF NONDERMATOPHYTE FILAMENTOUS FUNGI; APPROVED GUIDELINE. CLSI DOCUMENT M51-A, 2010.</li>
</ol>
<p class="First"> </p>
<p> </p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d5b70e4-8c33-415e-a4d7-5e1778454214"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Marketed by:</span></p>
<p>Astellas Pharma US, Inc.</p>
<p>Northbrook, IL 60062</p>
<p> </p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Gilead Sciences, Inc.</p>
<p>San Dimas, CA 91773</p>
<p>Am<span class="Bold">B</span>isome is a registered trademark of Gilead Sciences, Inc.</p>
<p>Abelcet<span class="Sup">®</span> is a registered trademark of The Liposome Company, Inc.</p>
<p>Revised: May 2012</p>
<p>12C019-AMB-SPL</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a120715b-21cd-43fb-a3df-133c3b43d1be"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure"><img alt="Individual Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a&amp;name=3ab7fe3b-149e-4ff5-826a-1e23a6d39b55-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMBISOME 		
					</strong><br><span class="contentTableReg">amphotericin b injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0469-3051</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AMPHOTERICIN B</strong> (AMPHOTERICIN B) </td>
<td class="formItem">AMPHOTERICIN B</td>
<td class="formItem">50 mg  in 12.5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0469-3051-30</td>
<td class="formItem">12.5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050740</td>
<td class="formItem">08/11/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Astellas Pharma US, Inc.
							(605764828)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3ab7fe3b-149e-4ff5-826a-1e23a6d39b55</div>
<div>Set id: f7be6506-4d20-401e-a0ff-02ad7c33158a</div>
<div>Version: 4</div>
<div>Effective Time: 20120531</div>
</div>
</div> <div class="DistributorName">Astellas Pharma US, Inc.</div></p>
</body></html>
